Background:Coronary artery disease (CAD) and prostate cancer (PCa) are not only common diseases, but share many risk factors. To date, only a few studies have explored the relationship between CAD and PCa risk, with conflicting results. Methods:The 4-year REDUCE study tested dutasteride 0.5 mg daily for PCa risk reduction in men with PSA of 2.5-10.0 ng/mL and a negative biopsy. Among men who underwent at least one on-study biopsy (n=6,729; 82.8%), the association between CAD and overall PCa risk and disease grade was examined using logistic and multinomial logistic regression adjusting for clinicopathological features, respectively. Results:Overall, 547 men (8.6%) had a history of CAD. Men with CAD were significantly older and had higher BMI, PSA and larger prostate volumes and were more likely to have diabetes, hypertension, and hypercholesterolemia and take aspirin and statins. On multivariate analysis, CAD was associated with a 35% increased risk of PCa diagnosis (OR: 1.35, 95% CI: 1.08-1.67, p=0.007), while elevating risk of both low- (OR: 1.34, 95% CI: 1.05-1.73, p=0.02), and high-grade disease (OR: 1.34, 95% CI: 0.95-1.88, p=0.09). Conclusions:In a post-hoc hypothesis developing secondary analysis of the REDUCE study, CAD was significantly associated with increased PCa diagnosis. Impact: If confirmed in other studies, this suggests CAD may be a novel PCa risk factor and suggests common shared etiologies. Whether lifestyle changes shown to reduce CAD risk (i.e. weight loss, exercise, cholesterol reduction, etc.) can reduce PCa risk, warrants further study.
- Received October 27, 2011.
- Revision received December 10, 2011.
- Accepted December 26, 2011.
- Copyright © 2011, American Association for Cancer Research.